Halia Therapeutics Reports Strong Phase 2 Data for Ofirnoflast in Lower-Risk MDS, Appoints New Chief Medical Officer — Halia Therapeutics, Inc.

Event summary

Halia Therapeutics to present final Phase 2 data for ofirnoflast (HT-6184) in lower-risk myelodysplastic syndrome (LR-MDS) at EHA2026, showing 67% hematological improvement and durable transfusion independence.
Ofirnoflast demonstrated no treatment-related serious adverse events in the Phase 2 trial, with a favorable safety profile.
Halia appoints Han Myint, MD, FACP, as Chief Medical Officer to lead clinical development as ofirnoflast advances toward pivotal trials.
Dr. Myint brings over three decades of experience in hematologic malignancies, oncology drug development, and late-stage clinical strategy.

The big picture

Halia Therapeutics' positive Phase 2 results for ofirnoflast position the company to advance into pivotal trials, addressing a significant unmet need in lower-risk MDS. The appointment of Han Myint as Chief Medical Officer strengthens Halia's clinical development capabilities, aligning with broader industry trends toward targeted therapies for inflammasome-driven diseases. The company's focus on innate immune biology and human genetic resilience provides a strategic foundation for expanding its pipeline beyond hematologic indications.

What we're watching

Clinical Development: Whether the robust Phase 2 data for ofirnoflast will translate into successful pivotal trials and regulatory approval.
Executive Impact: How Han Myint's extensive experience in hematologic malignancies and drug development will shape Halia's clinical strategy and pipeline progression.
Market Positioning: The pace at which Halia can differentiate ofirnoflast in the competitive landscape of lower-risk MDS treatments.